CTNM Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next? Contineum Therapeutics, Inc. (NASDAQ:CTNM) has received the result biotech investors never want to see: one of its partnered drugs missed the primary endpoint of a Phase 2 trial. JNJ-5120/PIPE-307, which Contineum developed and Johnson & Johnson (NYSE:JNJ) is advancing under a global license and development agreement, failed to demonstrate the required efficacy in the Phase […] | ||
Sector Update: Healthcare Stocks Ease Late Afternoon Healthcare stocks were edging lower late Tuesday afternoon, with the NYSE Healthcare Index and the S | ||
 FDA clears first generic radioligand drug; Sionna turns to layoffs A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise. | ||
 Johnson & Johnson Partner Contineum Slides as Depression Drug Fails Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. CTNM Stock Drops After Phase 2 MOONLIGHT-1 Results The company said its Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder. JNJ-5120/PIPE-307 is being developed by Johnson & J | ||
 CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection? Contineum said that Johnson & Johnson’s (JNJ) mid-stage trial of JNJ-5120, also known as PIPE-307, failed to meet its main goal in major depressive disorder. | ||
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making | ||